Özge Rencüzoğulları

8PUBLICATIONS
22CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Genome structure and regulationPredictive and prognostic markersCancer cell biologyMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Aug 02, 2023
Gemcitabine in combination with epibrassinolide enhanced the apoptotic response in an ER stress-dependent manner and reduced the epithelial-mesenchymal transition in pancreatic cancer cells.

Pınar Obakan Yerlikaya, Leila Mehdizadehtapeh, Özge Rencüzoğullari

|Aug 02, 2023
The protective impact of growth hormone against rotenone-induced apoptotic cell death via acting on endoplasmic reticulum stress and autophagy axis.

Özge Berrak Rencüzoğullari, Selay Tornaci, Yağmur Çelik

|Aug 02, 2023
Palbociclib suppresses the cancer stem cell properties and cell proliferation through increased levels of miR-506 or miR-150 in Panc-1 and MiaPaCa-2 cells.

Özge Rencüzoğullari, Elif Damla Arisan

|Feb 09, 2021
MiR-21 Is Required for the Epithelial-Mesenchymal Transition in MDA-MB-231 Breast Cancer Cells.

Elif Damla Arisan, Ozge Rencuzogullari, Clara Cieza-Borrella

|Feb 04, 2021
Palbociclib negatively regulates fatty acid synthesis due to upregulation of AMPKα and miR-33a levels to increase apoptosis in Panc-1 and MiaPaCa-2 cells.

Ozge Rencuzogulları, Pınar Obakan Yerlikaya, Ajda Çoker Gürkan

|Jul 03, 2019
Palbociclib, a selective CDK4/6 inhibitor, restricts cell survival and epithelial-mesenchymal transition in Panc-1 and MiaPaCa-2 pancreatic cancer cells.

Ozge Rencuzogulları, Pınar Obakan Yerlikaya, Ajda Çoker Gürkan

Pageof 2

Frequent Collaborators

8 joint publications

Elif Damla Arısan

6 joint publications

Pınar Obakan-Yerlikaya

4 joint publications

Ajda Çoker-Gürkan

2 joint publications

Narçin Palavan-Ünsal